<DOC>
	<DOC>NCT01135368</DOC>
	<brief_summary>The purpose of this study is to measure the safety, efficacy and quality of life of lansoprazole in patients with reflux disease over a five year period.</brief_summary>
	<brief_title>Safety and Efficacy of Lansoprazole in Patients With Reflux Disease</brief_title>
	<detailed_description>Lansoprazole is currently approved in Germany for the treatment of erosive reflux esophagitis and active duodenal and gastric ulcer disease, and for long-term treatment including maintenance of healed reflux esophagitis and duodenal ulcer disease and treatment of pathological hypersecretory conditions such as Zollinger-Ellison syndrome. This study was conducted to evaluate the safety, efficacy and quality of life of patients receiving up to five years of treatment with lansoprazole.</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>Had Gastro Esophageal Reflux disease with or without oesophagitis. Had a history of heartburn at least for 5 days per week during the past 6 months or was receiving longterm treatment with a proton pump inhibitor and during two weeks (without proton pump inhibitor treatment) prior to enrolment. History of surgery of stomach or oesophagus. Gastric ulcer (can be included after healing of gastric ulcer). Duodenal ulcer (can be included after healing of duodenal ulcer). Bleeding (melena, hematemesis). Severe concomitant disease (cancer, cardiovascular, renal, hepatic diseases). Barrett oesophagus with dysplasia. Complicated esophagitis (oesophageal strictures or ulcers). Treatment with proton pump inhibitor or Histamine receptor 2 (H2)antagonists within the previous two weeks. Pregnancy, wish to become pregnant, breast feeding. Treatment with non steroidal antiinflammatory drugs, treatment with acetylsalicylic acid (aspirin) &gt; 100 mg/day.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>GERD</keyword>
	<keyword>Gastroesophageal Reflux Disease</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>